Last updated: February 14, 2026
What is NDC 58151-0354?
The National Drug Code (NDC) 58151-0354 corresponds to Zepzelca (lurbinectedin), developed by PharmaMar. It is an anticancer agent approved by the FDA for treatment of metastatic small cell lung cancer (SCLC) in adults who have progressed on platinum-based chemotherapy.
Market Overview
Indication and Approved Use:
Zepzelca is indicated specifically for relapsed or refractory SCLC. The drug benefits from FDA approval since June 2020, expanding options for a high unmet need in SCLC therapy.
Market Size & Patient Population:
- Annual incidence of SCLC: Approximately 25,000 cases in the U.S.
- Population eligible for Zepzelca: Likely to be around 15,000-20,000 patients annually, considering the proportion with relapsed disease and overall health status.
- Market penetration: Initial uptake has been moderate, owing to prescribing patterns favoring established chemotherapy agents and immunotherapies.
Competitive Landscape:
- Key competitors: Topotecan, lurbinectedin (under study for additional labels), immunotherapies such as atezolizumab and durvalumab paired with chemotherapy.
- Market share: Zepzelca's share remains limited but growing among third-line SCLC agents.
Pricing Strategy and Cost Analysis
Current Wholesale Acquisition Cost (WAC):
- Per vial price: Estimated at approximately $9,500 (per 3.2 mg vial).
- Average treatment course: 2–4 cycles, depending on patient response.
- Cost per treatment: Roughly $19,000–$38,000, based on typical dosing.
Pricing Comparison:
- Topotecan (generic): Around $2,800 per cycle.
- Atezolizumab + chemotherapy: $15,000–$25,000 per cycle in combination therapies.
Reimbursement Landscape:
Highly dependent on insurance coverage and patient assistance programs. Payers tend to favor cost-effective options, which can limit reimbursement for new agents initially.
Market Projections
Revenue Forecasts (2023–2028):
| Year |
Estimated Prescriptions |
Estimated Revenue (USD) |
Key Assumptions |
| 2023 |
3,000–4,000 |
$57M–$152M |
Moderate prescriber adoption, initial launch phase |
| 2024 |
5,000–7,000 |
$95M–$266M |
Increased awareness, expanding payer coverage |
| 2025 |
8,000–10,000 |
$152M–$380M |
Greater familiarity and expanded indication inclusion |
| 2026 |
10,000–12,000 |
$190M–$456M |
Market penetration stabilizes, possible label expansion |
| 2027 |
12,000–15,000 |
$228M–$570M |
Widespread adoption, potential for combination therapies |
Factors Influencing Growth:
- Expansion of indications.
- Clinical trial success leading to label extension.
- Competitive pricing and formulary listing.
- Payer reimbursement policies and patient assistance programs.
Risks and Opportunities
Risks:
- Delay in formulary acceptance.
- Competition from emerging therapies or generics.
- Cost containment efforts, especially for in-market therapies.
Opportunities:
- Broadening indications to other SCLC treatments.
- Combination therapy development for first-line treatment.
- Positive clinical outcomes improving market penetration.
Key Takeaways
- NDC 58151-0354 (Zepzelca) targets a niche but high-need patient segment in SCLC.
- Pricing currently aligns with niche anticancer agents, with annual treatment costs reaching nearly $40,000 per patient.
- Market size remains limited but is projected to grow with increased prescriber acceptance.
- Revenue for Zepzelca could approach several hundred million USD annually by 2027, contingent on clinical progress and formulary access.
- Competitive landscape favors slow but steady growth, emphasizing clinical efficacy and payer negotiations.
FAQs
1. How does the price of Zepzelca compare to similar therapies?
Its per-vial cost (~$9,500) exceeds generic chemotherapies but aligns with other targeted anticancer treatments, reflecting specialized manufacturing and clinical niche.
2. What factors could push the market size higher?
Label expansions, combination approvals, and increased awareness through clinical success could increase the number of treated patients.
3. Are there any planned clinical trials for Zepzelca?
Yes, ongoing trials evaluate its efficacy in other tumor types and combination regimens, potentially broadening its use.
4. What is the baseline reimbursement environment?
Reimbursement varies but is increasingly favorable as clinical data demonstrate benefits over existing therapies, supported by value-based pricing initiatives.
5. How could biosimilar or generic entries affect Zepzelca’s market?
Since Zepzelca is relatively new and patented, biosimilar competition is unlikely soon but could emerge within 8–10 years, impacting long-term pricing.
Citations:
- FDA Label for Zepzelca.
- IQVIA National Sales Perspective (2022).
- CDC Data on SCLC incidence.
- Industry pricing reports (2023).
- ClinicalTrials.gov entries for Zepzelca trials.
